IDH1 and cholangiocarcinoma: Consistently, the lipid ROS levels in erastin-treated IDH1 mutation cell line was increased compared to that in erastin-treated IDH1 knockout or WT cell line, indicating that IDH1 mutation could aggravate erastin-induced ferroptosis in cholangiocarcinoma by increasing lipid ROS.